BDX is a medical technology (MedTech) company spanning medical supplies, devices, laboratory equipment, and diagnostics. Because its published analyst targets cluster near the current price, the ordinary "average analyst price target" does not meet a meaningful upside threshold. The overall mean of verified targets sits near $194, essentially at or below the latest price.
The $225 figure therefore comes from public discussion rather than consensus. It matches the high end of the published analyst range (stockanalysis.com and others list a $225 high), a $225 fair-value estimate referenced in independent valuation commentary, and a 12-month target of roughly $225 from 24/7 Wall St. These are individual, optimistic scenarios, not a Street-wide forecast. For context, more recent individual targets span from Barclays at $165 (initiated at Underweight/Sell in October 2026) up to Jefferies at $210 and Morgan Stanley at $210, with BofA at $200, Citi at $208, and UBS at $205.
At the latest verified close of $197.88, moving to $225 implies about 13.7% upside — a substantial move that would take the stock decisively above its 52-week high near $200. The path would likely require renewed revenue acceleration, better-than-expected EPS in fiscal 2027, or multiple expansion. BDX reported a fiscal third-quarter beat and raised its full-year outlook, yet consensus still forecasts fiscal 2026 EPS around $12.60, down from $14.40 the prior year, reflecting a reset year.
Several factors could underpin a higher price. Management's margin and productivity program, portfolio breadth across MedTech and diagnostics, and pricing power are recurring bull arguments. The company's capital-return story — a roughly 2.1% dividend yield and an active buyback authorization — provides support. Recent target increases from Citi ($204 to $208), UBS ($190 to $205), and BofA ($185 to $200) show some analysts turning more constructive after the fiscal Q3 beat and guidance raise. Improved sentiment across large-cap MedTech would also help.
The obstacles are real. Expected EPS is set to decline in fiscal 2026 before any projected recovery, and Barclays' October 2026 initiation at $165 with a bearish rating signals concern that valuation already reflects an improving story. Execution risk around growth cadence, headwinds in certain product lines, and a stretched trailing P/E (price-to-earnings) ratio near 46 could cap multiple expansion. If fiscal 2027 revenue growth comes in at the low single digits, the $225 objective would look demanding.
The stock's 52-week range of roughly $127.59 to $200.47 means $225 sits well above the prior high — reaching it would require a breakout into uncharted territory. The $200 area is the immediate psychological and resistance zone; a sustained close above it would be the first structural step. On the downside, the $180 to $190 band, where several targets cluster, represents a potential support zone.
Analyst price targets typically reflect a research horizon of around 12 months, though the $225 figure here is a public-discussion objective rather than a timed consensus. The next earnings report, due November 5, 2026, is the near-term focal point, along with any guidance for fiscal 2027, analyst revisions, margin commentary, and the pace of buybacks. Broader MedTech procedure volumes and interest-rate expectations also matter for a defensive, higher-multiple name.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, track positions, and identify shifting trends more efficiently than manual review allows. For investors following BDX or scanning the broader market, it offers a structured way to stay current on signal changes.
Can BDX reach $225? The objective represents roughly 13.7% upside from the latest price and is grounded in the optimistic end of public discussion — the high analyst target and independent fair-value estimates — rather than a consensus mean near $194. Support comes from margin initiatives, a recent earnings beat and guidance raise, and shareholder returns, while a down EPS year, a bearish $165 initiation, and a wide $157-to-$225 range underscore genuine disagreement. Whether $225 is attainable depends on execution and growth reacceleration, not on any guarantee. Investors should watch the November earnings report and fiscal 2027 guidance closely.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, BDX has been loosely correlated with COO. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if BDX jumps, then COO could also see price increases.
| Ticker / NAME | Correlation To BDX | 1D Price Change % | ||
|---|---|---|---|---|
| BDX | 100% | +0.36% | ||
| COO - BDX | 55% Loosely correlated | +2.94% | ||
| TMO - BDX | 50% Loosely correlated | -2.06% | ||
| BAX - BDX | 48% Loosely correlated | +5.30% | ||
| CNMD - BDX | 48% Loosely correlated | +5.19% | ||
| MMSI - BDX | 48% Loosely correlated | -2.24% | ||
More | ||||
| Ticker / NAME | Correlation To BDX | 1D Price Change % |
|---|---|---|
| BDX | 100% | +0.36% |
| Pharmaceuticals: Other industry (49 stocks) | 34% Loosely correlated | +0.27% |
| Pharmaceuticals industry (153 stocks) | -1% Poorly correlated | +0.67% |